Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CLOV.O
CLOV.O logo

CLOV.O Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.760
Open
1.670
VWAP
1.71
Vol
3.29M
Mkt Cap
902.43M
Low
1.660
Amount
5.63M
EV/EBITDA(TTM)
--
Total Shares
524.67M
EV
782.17M
EV/OCF(TTM)
--
P/S(TTM)
0.45
Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.
Show More

Events Timeline

(ET)
2026-03-04
08:40:00
Clover Health Partners with CMS for Data Interoperability
select
2026-02-26 (ET)
2026-02-26
17:10:00
Sees FY26 Adjusted EBITDA of $50M-$70M
select
2026-02-26
17:00:00
Clover Health Q4 Revenue $487.7M Beats Expectations
select
2026-01-14 (ET)
2026-01-14
16:20:00
Major Averages Decline for Second Straight Day
select
2026-01-14
12:10:00
Major Averages Decline for Second Straight Day as Investor Sentiment Softens
select

News

seekingalpha
5.0
04-01seekingalpha
Clover Health CFO Resignation and Interim Appointment Announced
  • Executive Change: Clover Health announced that CFO Peter Kuipers will resign effective March 30, 2026, while remaining in an advisory role until April 24, 2026, to ensure a smooth transition in financial management.
  • Interim Appointment: The Board has appointed Clay Thornton, the current CFO of Clover’s insurance plan, as interim CFO effective immediately, aimed at maintaining financial stability during the executive transition.
  • Market Reaction: Clover Health's stock rose 1.136% in premarket trading to $1.78, reflecting investor confidence in the company's future despite potential short-term uncertainties associated with the executive change.
  • Future Outlook: Clover Health expects a 46% membership growth and its first full year of GAAP profitability in 2026, indicating positive progress in improving financial performance and market positioning.
Newsfilter
5.0
04-01Newsfilter
Clover Health CFO Peter Kuipers Steps Down, Clay Thornton Appointed Interim
  • Executive Transition: Clover Health's CFO Peter Kuipers stepped down on March 30, 2026, but will remain as an advisor until April 24, ensuring a smooth transition and indicating stability during executive changes.
  • Interim Appointment: The Board appointed Clay Thornton, the current CFO of Clover's insurance plan, as Interim CFO effective immediately, reflecting the company's trust in his extensive experience in Medicare Advantage.
  • Financial Guidance Reaffirmed: Clover Health reiterated its financial guidance for fiscal year 2026, emphasizing its commitment to sustainable profitability and market growth, which reflects confidence in future performance.
  • Leadership Support: CEO Andrew Toy expressed gratitude for Kuipers' contributions and highlighted Thornton's leadership and industry experience, which will aid the company's success in the next phase, showcasing a positive outlook for future developments.
PRnewswire
7.5
03-27PRnewswire
VentriPoint Diagnostics Expands Remote Healthcare Services with AI Partnership
  • Shift in Healthcare Model: Ernst & Young's 2026 outlook indicates that outpatient clinics and ambulatory services are rapidly becoming the primary growth engines of the U.S. healthcare sector, attracting significant strategic capital and prompting a realignment of healthcare infrastructure.
  • AI Adoption Surge: According to NVIDIA's survey, 70% of healthcare organizations are actively deploying artificial intelligence, with over half reporting clear returns on investment from AI-powered diagnostic imaging, highlighting robust growth potential in the medical technology space.
  • Innovative Partnership Model: VentriPoint's collaboration with First Light Health aims to develop a hub-and-spoke care model centered around the VMS+™ system, enabling patients in remote areas to access advanced cardiac imaging locally, reducing costs and speeding up diagnosis.
  • Global Expansion Plans: Following validation of its model, VentriPoint plans to scale its services to underserved communities worldwide, showcasing its innovative capabilities in cardiac diagnostics and commitment to improving healthcare accessibility.
Newsfilter
7.5
03-27Newsfilter
VentriPoint Diagnostics Expands Remote Healthcare Services
  • Healthcare Model Shift: Ernst & Young's 2026 outlook indicates that outpatient clinics and ambulatory services are rapidly becoming the primary growth engines of the U.S. healthcare sector, attracting significant strategic capital and prompting a realignment of healthcare infrastructure.
  • AI Adoption Surge: According to NVIDIA's survey, 70% of healthcare organizations are actively deploying artificial intelligence, with over half reporting measurable returns on investment from AI-powered diagnostic imaging, highlighting a pivotal transformation in the medical technology space.
  • Innovative Partnership Model: VentriPoint's collaboration with First Light Health aims to develop a hub-and-spoke care model centered around the VMS+™ system, enabling remote patients to receive cardiac ultrasound scans locally, significantly reducing costs and turnaround times, with plans to scale this model globally.
  • Significant Technological Advantage: The VMS+™ system converts standard 2D echocardiograms into 3D volumetric images, achieving accuracy comparable to cardiac MRI at a fraction of the cost, which is crucial for early diagnosis in areas with high rates of heart disease and limited access to specialists, thus providing substantial social value.
Newsfilter
7.5
03-04Newsfilter
Clover Health Partners with Kno2 for Real-Time Data Interoperability
  • Real-Time Data Interoperability: Clover Health becomes the first payer to respond in real-time to patient requests on a CMS Aligned Network and TEFCA, utilizing standardized FHIR formats to enhance patient access to clinical and claims data, marking a significant achievement in nationwide interoperable data exchange.
  • Technological Infrastructure Advantage: Powered by its subsidiary Counterpart Health, Clover Health ensures secure and efficient routing of patient requests across the CMS Aligned Network, facilitating coordination among care teams and improving the quality of value-based healthcare services.
  • Industry Benchmark Role: Clover Health's early adoption signals that interoperable, patient-directed data exchange is not only feasible but achievable, driving the healthcare industry towards more efficient data management practices.
  • Demonstration Event Schedule: Clover Health, Kno2, and Counterpart Health will conduct live demonstrations at HIMSS 2026 from March 10-12, showcasing how patient requests flow through the network and return structured clinical and claims data, further validating their technological capabilities.
NASDAQ.COM
8.0
02-27NASDAQ.COM
United Airlines and Clover Health Options Trading Active
  • United Airlines Options Volume: As of today, United Airlines (UAL) options volume reached 32,010 contracts, representing approximately 3.2 million shares, which is about 55.3% of its average daily trading volume over the past month, indicating significant market interest.
  • High Volume Contracts: Notably, the $125 strike call option expiring on March 20, 2026, has seen 1,966 contracts traded today, equating to approximately 196,600 underlying shares, reflecting investor expectations for future price increases.
  • Clover Health Options Activity: Clover Health (CLOV) options trading volume stands at 31,299 contracts, representing around 3.1 million shares or approximately 53.7% of its average daily trading volume over the past month, showcasing the stock's market activity.
  • Key Contract Insights: The $2.50 strike call option expiring on March 6, 2026, has recorded a trading volume of 6,629 contracts today, amounting to approximately 662,900 shares, indicating investor confidence in the stock's short-term upward potential.
Wall Street analysts forecast CLOV.O stock price to rise
2 Analyst Rating
Wall Street analysts forecast CLOV.O stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
3.00
Averages
3.35
High
3.70
Current: 0.000
sliders
Low
3.00
Averages
3.35
High
3.70
Canaccord
Buy
downgrade
AI Analysis
2026-03-20
Reason
Canaccord
Price Target
AI Analysis
2026-03-20
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Clover Health to $3.20 from $3.70 and keeps a Buy rating on the shares. The firm said Clover took some lumps in 2025 alongside the rest of managed care with heightened medical costs, but the company closed out the year on a solid note without further deterioration. Heading into 2026, the company has strong tailwinds, namely being paid as a 4-star plan and favorable 2026 rates from CMS. In their view, the story is plausible and compelling.
UBS
Jonathan Yong
Neutral
downgrade
$3
2026-02-27
Reason
UBS
Jonathan Yong
Price Target
$3
2026-02-27
downgrade
Neutral
Reason
UBS analyst Jonathan Yong lowered the firm's price target on Clover Health to $2.75 from $3 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CLOV.O
Unlock Now

Valuation Metrics

The current forward P/E ratio for Clover Health Investments Corp (CLOV.O) is 81.97, compared to its 5-year average forward P/E of -6.16. For a more detailed relative valuation and DCF analysis to assess Clover Health Investments Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.16
Current PE
81.97
Overvalued PE
21.09
Undervalued PE
-33.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
8.28
Current EV/EBITDA
-2.47
Overvalued EV/EBITDA
28.45
Undervalued EV/EBITDA
-11.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.79
Current PS
0.27
Overvalued PS
1.77
Undervalued PS
-0.19

Financials

AI Analysis
Annual
Quarterly

Whales Holding CLOV.O

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Clover Health Investments Corp (CLOV.O) stock price today?

The current price of CLOV.O is 1.72 USD — it has increased 1.18

What is Clover Health Investments Corp (CLOV.O)'s business?

Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.

What is the price predicton of CLOV.O Stock?

Wall Street analysts forecast CLOV.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLOV.O is3.35 USD with a low forecast of 3.00 USD and a high forecast of 3.70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Clover Health Investments Corp (CLOV.O)'s revenue for the last quarter?

Clover Health Investments Corp revenue for the last quarter amounts to 496.65M USD, increased 50.05

What is Clover Health Investments Corp (CLOV.O)'s earnings per share (EPS) for the last quarter?

Clover Health Investments Corp. EPS for the last quarter amounts to -0.05 USD, increased 150.00

How many employees does Clover Health Investments Corp (CLOV.O). have?

Clover Health Investments Corp (CLOV.O) has 570 emplpoyees as of April 05 2026.

What is Clover Health Investments Corp (CLOV.O) market cap?

Today CLOV.O has the market capitalization of 902.43M USD.